mmj

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi

2148-8118 2618-6020

Muğla Sıtkı Koçman Üniversitesi

Surgery

Cerrahi

Synchronous Deep Venous Thrombosis and Pulmonary Embolism in Stomach Cancer Patient: Case Report

Senkron Derin Ven Trombozu ve Pulmoner Embolisi Olan Mide Kanserli Hasta: Olgu Sunumu

https://orcid.org/0000-0003-4712-0512

Gökçe

Kağan

T.C. SAĞLIK BAKANLIĞI MUĞLA SITKI KOÇMAN ÜNİVERSİTESİ EĞİTİM VE ARAŞTIRMA HASTANESİ GENEL CERRAHİ KLİNİĞİ

https://orcid.org/0000-0001-9606-4428

Aydın

Cihan

T.C. SAĞLIK BAKANLIĞI MUĞLA SITKI KOÇMAN ÜNİVERSİTESİ EĞİTİM VE ARAŞTIRMA HASTANESİ GENEL CERRAHİ KLİNİĞİ

https://orcid.org/0000-0002-9446-2294

Doğan

Emrah

T.C. SAĞLIK BAKANLIĞI MUĞLA SITKI KOÇMAN ÜNİVERSİTESİ EĞİTİM VE ARAŞTIRMA HASTANESİ RADYOLOJİ KLİNİĞİ

https://orcid.org/0000-0002-6035-1123

Yazman

Serkan

T.C. SAĞLIK BAKANLIĞI MUĞLA SITKI KOÇMAN ÜNİVERSİTESİ EĞİTİM VE ARAŞTIRMA HASTANESİ KALP DAMAR CERRAHİSİ KLİNİĞİ

12 31 2019

6 3 156 159 10 01 2018 10 31 2018

2014

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi

Venousthromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonaryembolism (PE). The annual incidence of VTE in the general population is 117 per100000. VTE is an important cause of morbidity and mortality. The incidence ofcancer-associated VTE is higher and the results are more dramatic. Stomach canceris the sixth most common type of cancer that causes death. The most commonhistological subtype of stomach cancer is adenocarcinoma. Stomach cancer is thethird type of cancer that has the highest risk of cancer relatedthromboembolism after pancreatic and lung cancer. The main treatment in cancerrelated VTE is low molecular weight heparin (LMWH). The aim of this case reportis to present a 76 years old male patient with stomach cancer, synchronousvenous thrombosis and pulmonary embolism, who underwent surgery under LMWHtreatment.

Venöz tromboemboli (VTE), derin ven trombozu(DVT) ve pulmoner emboli (PE)’den oluşur. VTE’nin genel popülasyonda yıllıkgörülme oranı her 100.000’de 117’dir. VTE önemli bir morbidite ve mortalitekaynağıdır. Kanserle ilişkili gelişen VTE’nin görülme insidansı daha fazladırve sonuçları daha dramatiktir. Mide kanseri en sık görülen ve ölüme yol açanaltıncı kanser tipidir. Mide kanserinin en sık görülen histolojik subtipiadenokarsinomdur. Mide kanseri, pankreas ve akciğer kanserinden sonra kanserebağlı tromboemboli riski en yüksek olan üçüncü kanser tipidir. Kansere bağlıgelişen VTE’de esas tedavi düşük molekül ağırlıklı heparindir (DMAH). Bu vakatakdiminin amacı; DMAH tedavisi altında ameliyat edilen, 76 yaşında, senkronvenöz trombozu ve pulmoner embolisi olan mide kanserli erkek hastayı sunmaktır.

Derin Ven Trombozu Mide Kanseri Pulmoner Emboli

Deep Venous Thrombosis Pulmonary Embolism Stomach Cancer

1. Wu C, Lee AY. Novel or Non–Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis Semin Thromb Hemost. 2015;41(2):237–43.

2. Walker AJ, Card TR, West J, Crooks C, Grainge MJ.Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 2013;49(6):1404–13.

3. Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies–systematic review and meta-analysis. Acta Oncologica. 2014;53(9):1230–7.

4. Farge D, Bounameaux H, Brenner B, et al. Implementing Thrombosis Guidelines in Cancer Patients: A Review. Rambam Maimonides Med J. 2014;5(4):0041.

5. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1):132–75.

6. Wada T, Fujiwara H, Morita S, Fukagawa T, Katai H.Incidence of and risk factors for preoperative deep venous thrombosis in patients undergoing gastric cancer surgery. Gastric Cancer 2017;20(5):872–7.

7. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346(8981):1004–5.

8. Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008;34(2):143–5.

9. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev. 2001;15(2):61–7.

10. Khorana AA, Liebman HA, White RH, et al. The Risk of Venous Thromboembolism in Patients with Cancer. American Society of Clinical Oncology; ASCO Educational Book; 2008;240–8.

11. Marshall-Webb M, Bright T, Price T, et al. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017;30(2):1–7.

12. Elyamany G, Alzahrani A.M, Bukhary E. Cancer-Associated Thrombosis: An Overview. Clin Med Insights Oncol. 2014;8:129-37.

13. Martin MJ, Blair KS, Curry TK, Singh N. Vena cava filters: current concepts and controversies for the surgeon. Curr Probl Surg. 2010;47(7):524–618.

14. Rojas-Hernandez CM, Zapata-Copete JA, García-Perdomo HA. Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;130:44–50.